Tirzepatide (5mg)
Tirzepatide is a 39-amino acid dual incretin receptor agonist that activates both GLP-1 and GIP receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Its ~5-day half-life allows for convenient weekly subcutaneous administration. Clinical trials show superior glycemic control and weight reduction compared to selective GLP-1 agonists.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full Tirzepatide encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
Tirzepatide is a novel dual agonist that simultaneously activates GLP-1 and GIP receptors. This dual mechanism enhances glucose-dependent insulin secretion while suppressing glucagon release, slowing gastric emptying, and promoting satiety via central appetite regulation. The additional GIP activity synergistically enhances metabolic effects beyond GLP-1 alone, contributing to the superior weight reduction observed in clinical trials. Its ~5-day half-life allows for convenient weekly administration.
Quick Start
- Reconstitution: Add 2.0 mL bacteriostatic water → 2.5 mg/mL concentration.
- Typical weekly range: 2.5–15 mg once weekly (gradual titration every 4 weeks).
- Storage: Lyophilized: freezer at −20 °C; after reconstitution, refrigerate at 2–8 °C; use within 28 days.
Typical / Graduated Approach (2 mL = 2.5 mg/mL)
Route: Subcutaneously | Frequency: Once weekly
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–4 | 2.5 mg | 100 Units (1.00 mL) |
| Weeks 5–8 | 5 mg | 2 × 100 Units (1.00 mL) |
| Weeks 9–12 | 7.5 mg | 3 × 100 Units (1.00 mL) — 1.5 vials |
| Weeks 13–16 | 10 mg | 4 × 100 Units (1.00 mL) — 2 vials |
| Maintenance 17+ | 10 mg | 4 × 100 Units (1.00 mL) — 2 vials |
Studies report administration once weekly subcutaneously on the same day each week. For doses requiring multiple administrations, these are given sequentially. Dose increases occur every 4 weeks to minimize gastrointestinal side effects. Higher doses (12.5–15 mg/week) are reported where tolerated.
Related compounds
Reconstitution Steps
- Withdraw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the side of the vial; avoid foaming.
- Gently swirl/rotate until dissolved (do not shake vigorously).
- Note reconstitution date and refrigerate at 2–8 °C, protecting from light.
- Use within 28 days of reconstitution.
Protocol Overview
- Objective: Support glycemic control, weight management, and metabolic health via dual incretin receptor activation.
- Schedule: Weekly subcutaneous injection on the same day for 12–16+ weeks.
- Storage: Lyophilized frozen; reconstituted refrigerated up to 28 days.
Dosing Protocol
- Initiation: 2.5 mg once weekly for 4 weeks (starting dose).
- Titration: Increase by 2.5 mg every 4 weeks if tolerated.
- Maintenance: 5–15 mg weekly based on response and tolerability.
- Frequency: Once weekly (subcutaneous), same day each week.
- Break between cycles: After completing the cycle, a pause of 4–8 weeks is recommended. Tirzepatide (a GIP/GLP-1 dual agonist) has a half-life of ~5 days — sufficient clearance time is required before a new cycle.
Washout & Cycle Restart
When can I restart?
After completing the cycle, a pause of 4–8 weeks is recommended. Tirzepatide (a GIP/GLP-1 dual agonist) has a half-life of ~5 days — sufficient clearance time is required before a new cycle.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C; do not freeze the reconstituted solution.
- Shelf Life: Use within 28 days after reconstitution.
- Allow vials to reach room temperature before opening.
Important Notes
- For multi-injection doses, use different sites on the same day.
- Gastrointestinal effects (nausea, diarrhea) are common initially; gradual titration minimizes them.
Potential Benefits & Side Effects
Potential Benefits:
- Glycemic control: Significant decreases in HbA1c in type 2 diabetes mellitus trials.
- Weight reduction: Clinical trials report significant body weight loss (up to ~11 kg more than a GLP-1 RA at 26 weeks on higher doses).
- Cardiovascular markers: Improvements in lipid profiles and blood pressure.
Potential Side Effects:
- Gastrointestinal: Nausea, diarrhea, vomiting, constipation — typically mild-to-moderate and dose-dependent; gradual titration reduces frequency.
- Injection site reactions: Occasional mild redness or irritation.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Thyroid C-cell tumors (medullary thyroid carcinoma)
Same warning as GLP-1 RAs. C-cell tumors in rodents. Contraindicated in MTC/MEN 2.
📄 FDA Boxed Warning — Mounjaro® LabelAcute pancreatitis
Risk of acute pancreatitis. Reported in post-marketing surveillance.
📄 FDA Label — Mounjaro®References
- StatPearls (NCBI Bookshelf) — Pharmacology, dosing, and clinical use of Tirzepatide
View Source - Frontiers in Endocrinology (2022) — GIP/GLP-1 agonist tirzepatide for T2DM and obesity
View Source - The Lancet (2018) — Efficacy and safety of tirzepatide in T2DM (Phase 2)
View Source - New England Journal of Medicine (2022) — Tirzepatide once weekly for the treatment of obesity
View Source - FDA Prescribing Information — Mounjaro (tirzepatide) prescribing information
View Source - Mayo Clinic — Tirzepatide — clinical overview and patient information
View Source
Recommended Supplements
Vitamin B12 (Methylcobalamin)
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Protein / Collagen
Fiber Supplement (Psyllium)
External Sources & Regulatory Status
Regulatory Approvals
Mounjaro® / Zepbound® · Type 2 diabetes / Obesity (2022)
Mounjaro® · Type 2 diabetes (2022)
Mounjaro® · Type 2 diabetes (2023)
Mounjaro® · Type 2 diabetes (2024)
Mounjaro® · Type 2 diabetes / Obesity (2023)
Mounjaro® · Type 2 diabetes (2023)
Approved worldwide (6+ countries)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →